ES531517A0 - Procedimiento para la obtencion de nuevos compuestos esteroides - Google Patents

Procedimiento para la obtencion de nuevos compuestos esteroides

Info

Publication number
ES531517A0
ES531517A0 ES531517A ES531517A ES531517A0 ES 531517 A0 ES531517 A0 ES 531517A0 ES 531517 A ES531517 A ES 531517A ES 531517 A ES531517 A ES 531517A ES 531517 A0 ES531517 A0 ES 531517A0
Authority
ES
Spain
Prior art keywords
procedure
obtaining new
steroid compounds
new steroid
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES531517A
Other languages
English (en)
Spanish (es)
Other versions
ES8602846A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of ES8602846A1 publication Critical patent/ES8602846A1/es
Publication of ES531517A0 publication Critical patent/ES531517A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/001—Lactones
    • C07J21/003—Lactones at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/007—3 membered carbocyclic rings in position 6-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES531517A 1983-04-13 1984-04-11 Procedimiento para la obtencion de nuevos compuestos esteroides Granted ES531517A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH198183 1983-04-13

Publications (2)

Publication Number Publication Date
ES8602846A1 ES8602846A1 (es) 1985-12-01
ES531517A0 true ES531517A0 (es) 1985-12-01

Family

ID=4223123

Family Applications (4)

Application Number Title Priority Date Filing Date
ES531517A Granted ES531517A0 (es) 1983-04-13 1984-04-11 Procedimiento para la obtencion de nuevos compuestos esteroides
ES544769A Expired ES8705460A1 (es) 1983-04-13 1985-07-01 Procedimiento para la obtencion de nuevos compuestos este- roides
ES544768A Expired ES8705459A1 (es) 1983-04-13 1985-07-01 Procedimiento para la obtencion de nuevos compuestos este- roides
ES544770A Expired ES8705461A1 (es) 1983-04-13 1985-07-01 Procedimiento para la obtencion de nuevos compuestos este- roides

Family Applications After (3)

Application Number Title Priority Date Filing Date
ES544769A Expired ES8705460A1 (es) 1983-04-13 1985-07-01 Procedimiento para la obtencion de nuevos compuestos este- roides
ES544768A Expired ES8705459A1 (es) 1983-04-13 1985-07-01 Procedimiento para la obtencion de nuevos compuestos este- roides
ES544770A Expired ES8705461A1 (es) 1983-04-13 1985-07-01 Procedimiento para la obtencion de nuevos compuestos este- roides

Country Status (23)

Country Link
US (1) US4559332A (forum.php)
EP (1) EP0122232B1 (forum.php)
JP (1) JPS59231100A (forum.php)
AR (4) AR241918A1 (forum.php)
AT (1) ATE39256T1 (forum.php)
AU (1) AU565017B2 (forum.php)
CA (1) CA1220781A (forum.php)
DD (2) DD251144A5 (forum.php)
DE (2) DE3475622D1 (forum.php)
DK (1) DK163988C (forum.php)
ES (4) ES531517A0 (forum.php)
FI (1) FI77669C (forum.php)
GR (1) GR81834B (forum.php)
HU (1) HU191406B (forum.php)
IE (1) IE57541B1 (forum.php)
IL (1) IL71504A (forum.php)
LU (1) LU91072I2 (forum.php)
NL (1) NL300144I2 (forum.php)
NO (1) NO159800C (forum.php)
NZ (1) NZ207826A (forum.php)
PH (1) PH19997A (forum.php)
PT (1) PT78413B (forum.php)
ZA (1) ZA842710B (forum.php)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670551A (en) * 1984-06-21 1987-06-02 Ciba-Geigy Corporation Epoxy steroids
US5248807A (en) * 1991-01-29 1993-09-28 Shionogi & Co., Ltd. Triterpene derivatives
US6245755B1 (en) 1992-04-21 2001-06-12 Curators Of The Unversity Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
US6150347A (en) * 1992-04-21 2000-11-21 The Curators Of The University Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
JPH05329410A (ja) * 1992-05-29 1993-12-14 Sekisui Plastics Co Ltd マスキング材
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
RO118046B1 (ro) * 1995-06-07 2003-01-30 Gd Searle & Co Chicago Asociere farmaceutica
WO1996040255A2 (en) * 1995-06-07 1996-12-19 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldosterone antagonist
US20050267302A1 (en) * 1995-12-11 2005-12-01 G.D. Searle & Co. Eplerenone crystalline form exhibiting enhanced dissolution rate
EP1167380A3 (en) * 1995-12-11 2004-12-08 G.D. Searle & Co. 11.alpha.-hydroxy-steroid-4,6-dien-3-one compounds and a process for their preparation
US20050159594A1 (en) * 1995-12-11 2005-07-21 Pharmacia Corporation Eplerenone crystal form exhibiting enhanced dissolution rate
US20020045746A1 (en) * 1995-12-11 2002-04-18 Barton Kathleen P. Eplerenone crystalline form
EA009176B1 (ru) * 1995-12-11 2007-12-28 Дж.Д.Серл Энд Ко. Способ получения 7-альфа-карбоксил-9,11-эпоксистероидов и промежуточных продуктов, используемых для их получения, и общий способ эпоксидирования по олефиновым двойным связям
US20020038021A1 (en) * 1995-12-11 2002-03-28 Barton Kathleen P. Eplerenone crystalline form exhibiting enhanced dissolution rate
AU747959B2 (en) * 1995-12-11 2002-05-30 G.D. Searle & Co. Processes and intermediates for the preparation of 9, 11-epoxy steroids
BR9714510A (pt) * 1996-12-11 2000-11-28 Searle & Co Processo e preparo de esteróides de 9,11-époxi e intermediários úteis dos mesmos
EP1223174A3 (en) * 1996-12-11 2005-03-16 G.D. Searle & Co. Processes for preparation of 3-keto-7alpha-alkoxycarbonyl-delta-4,5- steroids and intermediates useful therein
US6887991B1 (en) * 1996-12-11 2005-05-03 G. D. Searle & Company Processes for preparation of 9, 11-epoxy steroids and intermediates useful therein
ZA9711038B (en) * 1996-12-11 1999-01-25 Searle & Co Spr process for preparation of 9,11-Epoxy steroids and intermediates useful therein
US6368835B1 (en) * 1998-05-29 2002-04-09 Kyowa Hakko Kogyo Co., Ltd. Process for producing a lactone using corynebacterium sp. NK-1 (FERM BP-6329)
PL348198A1 (en) * 1998-11-06 2002-05-06 Searle & Co Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
CZ20012342A3 (cs) 1998-12-23 2001-12-12 G. D. Searle Llc Kombinace inhibitorů transportu ľlučové kyseliny v ileu a derivátů kyseliny fibrové pro kardiovaskulární indikace
AU2157400A (en) 1998-12-23 2000-07-31 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
JP2002533411A (ja) * 1998-12-23 2002-10-08 ジー．ディー．サール エルエルシー 心臓血管に適用するための組み合わせ
EP1340510A1 (en) 1998-12-23 2003-09-03 G.D. Searle LLC. Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
HK1040925B (en) 1998-12-23 2003-09-11 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
DE69908643T2 (de) 1998-12-23 2004-05-13 G.D. Searle Llc, Chicago Kombinationen von cholesteryl ester transfer protein inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen
PT1140188E (pt) 1998-12-23 2003-10-31 Searle Llc Combinacoes de inibidores do transporte de acidos biliares do ileo e de inibidores da proteina de transferencia de esteres de colesterilo para doencas cardiovasculares.
ATE228012T1 (de) 1998-12-23 2002-12-15 Searle Llc Kombinationen von ileumgallensäuretransports inhibitoren und gallensäure sequestriermitteln für kardiovaskuläre indikationen
US20030096798A1 (en) * 1999-11-09 2003-05-22 Williams Gordon H. Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
US20030203884A1 (en) * 1999-11-09 2003-10-30 Pharmacia Corporation Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
AU1756201A (en) * 1999-12-08 2001-06-18 Pharmacia Corporation Nanoparticulate eplerenone compositions
EP1505072A3 (en) * 1999-12-08 2006-06-21 Pharmacia Corporation Eplerenone crystalline form exhiniting enhanced dissolution rate
EP1527782A1 (en) * 1999-12-08 2005-05-04 Pharmacia Corporation Nanoparticulate eplerenone compositions
HUP0201457A3 (en) * 1999-12-08 2003-07-28 Pharmacia Corp Chicago Eplerenone crystalline form, pharmaceutical compositions containing them and their preparations
US20030083493A1 (en) * 1999-12-08 2003-05-01 Barton Kathleen P. Eplerenone drug substance having high phase purity
NZ530028A (en) * 1999-12-08 2005-08-26 Pharmacia Corp Process for producing eplerenone crystalline form exhibiting enhanced dissolution rate
AU2001240115A1 (en) 2000-03-10 2001-09-24 Pharmacia Corporation Method for the preparation of tetrahydrobenzothiepines
WO2001068096A2 (en) * 2000-03-10 2001-09-20 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
CA2409437A1 (en) * 2000-05-11 2001-11-22 Pharmacia Corporation Aldosterone antagonist composition for release during aldosterone acrophase
AU1604001A (en) * 2000-06-13 2001-12-24 Pharmacia Corp Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
EP1303306B1 (en) * 2000-07-27 2006-06-21 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
EP1313485B1 (en) * 2000-08-28 2005-10-12 Pharmacia Corporation Use of an aldosterone receptor antagonist to improve cognitive function
AU2002241768A1 (en) * 2000-10-30 2002-06-18 Pharmacia Corporation Aspergillus ochraceus 11 alpha hydroxylase and oxidoreductase
NZ525726A (en) * 2000-11-09 2004-10-29 Astrazeneca Ab Oral pharmaceutical composition containing a block copolymer
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US20040077625A1 (en) * 2001-07-25 2004-04-22 Tremont Samuel J. Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
US20030220310A1 (en) * 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
WO2003040127A1 (en) * 2001-11-02 2003-05-15 G.D. Searle Llc Novel mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (asbt) and taurocholate uptake
JP2005516914A (ja) 2001-12-12 2005-06-09 ファルマシア・コーポレーション エポキシ−ステロイド系アルドステロン受容体アンタゴニストで眼病を治療する方法
US6852753B2 (en) 2002-01-17 2005-02-08 Pharmacia Corporation Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
CA2479259A1 (en) * 2002-03-18 2003-10-02 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
BR0308515A (pt) * 2002-03-18 2005-02-01 Pharmacia Corp Combinação de um antagonista de receptor de aldosterona com ácido nicotìnico ou um derivado de ácido nicotìnico
EP1487540A2 (en) * 2002-03-20 2004-12-22 Pharmacia Corporation Storage stable eplerenone formulation
US7235655B2 (en) * 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
AU2003259022A1 (en) * 2002-03-22 2003-10-13 Pharmacia And Upjohn Company Llc Process to prepare eplerenone
CA2495412A1 (en) * 2002-08-16 2004-02-26 Pharmacia & Upjohn Company 5 androsten-3.beta.-ol steroid intermediates and processes for their preparation
US20070066579A1 (en) * 2002-08-16 2007-03-22 White Michael J 5-androsten-3beta-ol steroid intermediates and processs for their preparation
RU2304144C2 (ru) * 2002-11-06 2007-08-10 Фармация Энд Апджон Компани Ллс 7-карбоксизамещенные стероиды, способ их получения, способы получения эплеренона
RU2289586C2 (ru) * 2002-11-07 2006-12-20 Фармация Энд Апджон Компани Ллс Способ получения 7-замещенных стероидных соединений, соединения, способы получения эплеренона, продукт
CL2004000545A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
CL2004000544A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati
CL2004000574A1 (es) * 2003-03-21 2005-02-11 Pharmacia Corp Sa Organizada B Proceso para preparar un compuesto 17-espirolactona o la sal de lactona abierta por carbonilacion del correspondiente 17-alquenil o alquinil derivado, los intermediarios que se usan y su proceso de obtencion.
WO2004100871A2 (en) * 2003-05-09 2004-11-25 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
US20040265948A1 (en) * 2003-06-27 2004-12-30 White Michael Jon Microbial method for hydrolysis and oxidation of androst-5-ene and pregn-5-ene steroid esters
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
KR20060123647A (ko) * 2004-03-22 2006-12-01 파마시아 앤드 업존 캄파니 엘엘씨 9,11 에폭시 스테로이드의 개선된 제조 방법
US20070196471A1 (en) * 2004-04-02 2007-08-23 Thosar Shilpa S Micronized Eplerenone Compositions
US20050232957A1 (en) * 2004-04-14 2005-10-20 Katz Kenneth A Compositions and methods for moisturizing skin
CN1321128C (zh) * 2005-07-15 2007-06-13 浙江医药股份有限公司新昌制药厂 孕甾－4－烯－7，21－二甲酸，9，11－环氧－17－羟基－3－氧代，γ－内酯，甲酯，(7α,11α,17α)－的制备方法
WO2007025780A2 (en) * 2005-09-02 2007-03-08 Recordati Ireland Limited Aldosterone receptor antagonists
EP1842543A1 (en) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
US20070248665A1 (en) * 2006-04-24 2007-10-25 Sherman Bernard C Compositions comprising co-precipitate of eplerenone and a water-soluble excipient
DE102006028032A1 (de) * 2006-06-14 2007-12-20 Henkel Kgaa Aufhell- und/oder Färbemittel mit Nitrilen
US20100086586A1 (en) * 2006-12-21 2010-04-08 Brett Antony Mooney Pharmaceutical Composition
CA2582496A1 (en) * 2007-03-20 2008-09-20 Apotex Pharmachem Inc. Improved process for the preparation and purification of eplerenone
FR2917975B1 (fr) 2007-06-26 2009-10-16 Ceva Sante Animale Sa Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains
DE102008026793A1 (de) * 2008-06-02 2009-12-03 Bayer Schering Pharma Aktiengesellschaft C-Ring-substituierte Pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
CN101863951B (zh) * 2009-04-15 2012-06-06 浙江省天台县奥锐特药业有限公司 依普利酮的制备方法
ES2602826T3 (es) 2009-05-28 2017-02-22 Novartis Ag Derivados aminobutíricos sustituidos como inhibidores de neprilisina
CN102448928B (zh) 2009-05-28 2014-10-01 诺华股份有限公司 作为中性溶酶(neprilysin)抑制剂的取代的氨基丁酸衍生物
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
JP5913136B2 (ja) * 2010-02-08 2016-04-27 プレーリー ファーマシューティカルズ、エルエルシー 糖質コルチコイド感作物質としてのプロゲストーゲンの使用方法
JP6148175B2 (ja) 2010-05-10 2017-06-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 網膜中および／または網膜下における液体貯留の処置のための方法および組成物
JP6180930B2 (ja) 2010-06-16 2017-08-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 創傷治癒過程における再上皮化を刺激するための方法及び組成物
TR201007653A2 (tr) 2010-09-20 2012-04-24 Bi̇lgi̇ç Mahmut Eplerenon içeren farmasötik kompozisyon
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
WO2012107513A1 (en) * 2011-02-10 2012-08-16 Crystal Pharma, S.A.U. Process for obtaining drospirenone
ITMI20121037A1 (it) * 2012-06-14 2013-12-15 Ind Chimica Srl Processo per la preparazione di nitrili utili come intermedi per la sintesi di molecole ad attivita' farmacologica
BR112015019369A2 (pt) 2013-02-14 2017-07-18 Novartis Ag derivados de ácido bisfenil butanóico substituídos como inibidores de nep (endopeptidase neutra)
CN104262450A (zh) * 2014-09-19 2015-01-07 江苏嘉逸医药有限公司 依普利酮的制备及精制方法
ES2699923T3 (es) 2014-10-17 2019-02-13 Ind Chimica Srl Proceso para la preparación de 7alfa-(metoxicarbonil)-3-oxo-17alfa-pregn-4,9(11)-dien-21,17-carbolactona, un intermedio útil para la síntesis de moléculas con actividad farmacológica
WO2017055248A1 (en) 2015-09-28 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of heart failure
US20180280414A1 (en) 2015-10-13 2018-10-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
CN105753930A (zh) * 2016-03-30 2016-07-13 北京万全德众医药生物技术有限公司 依普利酮的一种合成方法
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
US20240366632A1 (en) 2021-08-31 2024-11-07 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of ocular rosacea

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3095412A (en) * 1961-12-19 1963-06-25 Searle & Co 9alpha, 11alpha-epoxy and 11beta-chloro-9alpha-hydroxy 17alpha-(2-carboxyethyl)-17beta-hydroxyandrost-4-en-3-one gamma-lactones and delta1 and delta6 analogs
GB1041534A (en) * 1963-04-24 1966-09-07 Merck & Co Inc 20-spiroxane compounds
US3729491A (en) * 1970-06-15 1973-04-24 Searle & Co 3,5-dioxo-a-nor-b-homo steroidal spirolactones
GB1368006A (en) * 1972-08-24 1974-09-25 Searle & Co 4alpha,7alpha-carbonyl-5-cyano-17-hzydroxy-3-oxo-5beta,17alpha- pregnane-21-carboxylic acid ypsilon-lactone
US3849404A (en) * 1973-03-09 1974-11-19 Searle & Co Purification of 6,7-dihydro-17-hydroxy-3-oxo-3'h-cyclopropa(6,7)-17alpha-pregna-4,6-diene-21-carboxylic acid gamma-lactones
DE2652761C2 (de) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE2922500A1 (de) * 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
DE3111951A1 (de) * 1981-03-23 1982-09-30 Schering Ag, 1000 Berlin Und 4619 Bergkamen 7(alpha)-alkoxycarbonyl-15ss-methylen-4-androstene, verfahren zu ihrer herstellung und verwendung als arzneimittel

Also Published As

Publication number Publication date
DD233375A5 (de) 1986-02-26
DK163988C (da) 1992-09-21
ZA842710B (en) 1984-11-28
DE122004000012I2 (de) 2006-06-08
NO159800B (no) 1988-10-31
JPH0212479B2 (forum.php) 1990-03-20
DE3475622D1 (en) 1989-01-19
LU91072I2 (fr) 2004-04-07
NO841465L (no) 1984-10-15
IE57541B1 (en) 1992-10-07
FI841400A0 (fi) 1984-04-09
IL71504A0 (en) 1984-07-31
CA1220781A (en) 1987-04-21
AU565017B2 (en) 1987-09-03
NL300144I1 (nl) 2004-06-01
FI77669C (fi) 1989-04-10
ES8705459A1 (es) 1987-05-01
NL300144I2 (nl) 2004-06-01
DK189484A (da) 1984-10-14
PT78413A (en) 1984-05-01
PT78413B (en) 1986-08-22
AU2685384A (en) 1984-10-18
DD251144A5 (de) 1987-11-04
GR81834B (forum.php) 1984-12-12
IL71504A (en) 1987-07-31
ES8602846A1 (es) 1985-12-01
FI77669B (fi) 1988-12-30
PH19997A (en) 1986-08-28
AR241918A1 (es) 1993-01-29
IE840906L (en) 1984-10-13
JPS59231100A (ja) 1984-12-25
US4559332A (en) 1985-12-17
ES8705460A1 (es) 1987-05-01
ES8705461A1 (es) 1987-05-01
EP0122232B1 (de) 1988-12-14
ES544770A0 (es) 1987-05-01
AR242222A1 (es) 1993-03-31
DK163988B (da) 1992-04-27
EP0122232A1 (de) 1984-10-17
AR242221A1 (es) 1993-03-31
DE122004000012I1 (de) 2012-05-16
NZ207826A (en) 1986-07-11
HU191406B (en) 1987-02-27
ATE39256T1 (de) 1988-12-15
NO159800C (no) 1989-02-08
DK189484D0 (da) 1984-04-12
ES544768A0 (es) 1987-05-01
ES544769A0 (es) 1987-05-01
AR242223A1 (es) 1993-03-31
FI841400L (fi) 1984-10-14

Similar Documents

Publication Publication Date Title
ES531517A0 (es) Procedimiento para la obtencion de nuevos compuestos esteroides
ES537830A0 (es) Procedimiento para la obtencion de derivados de 5-amino-4-hidroxivalerilo sustituidos
ES532183A0 (es) Procedimiento para la preparacion de compuestos cefemicos
ES546946A0 (es) Procedimiento para la obtencion de compuestos de fenilalqui-lo
ES533538A0 (es) Procedimiento para la obtencion de tetrahidropiridazinonas
ES535534A0 (es) Procedimiento para la obtencion de -aril-1h-azol-1-etanoles
ES525953A0 (es) Procedimiento para la obtencion de derivados piperazinicos
ES526042A0 (es) Procedimiento para la obtencion de azolilbutanoles
ES537829A0 (es) Procedimiento para la obtencion de compuestos de eglina
ES535704A0 (es) Procedimiento para la obtencion de derivados de piridinio
ES533988A0 (es) Procedimiento para la obtencion de mercaptocarboxilamidas
ES528654A0 (es) Procedimiento para la obtencion de derivados de tetrahidrocarbazol
ES543624A0 (es) Procedimiento para la obtencion de nuevos compuestos de aralquiltriazol
ES535185A0 (es) Procedimiento para la preparacion de nuevas oxadiacinas
ES525257A0 (es) Procedimiento para la obtencion de poliamido-imidas
ES532213A0 (es) Procedimiento para la obtencion de compuestos de amino-alquilo inferior-penem
ES527054A0 (es) Procedimiento para la obtencion de derivados bis-quinazolinicos
ES532212A0 (es) Procedimiento para la obtencion de compuestos de 2-heterociclil-alquilo inferior-2-penem
ES545611A0 (es) Procedimiento para la fabricacion de nuevos compuestos cina-moicos
ES528807A0 (es) Procedimiento para preparar compuestos de ftalocianina
ES535373A0 (es) Procedimiento para la preparacion de nuevas pirazolil- e isoxazolilsulfonilureas
ES537129A0 (es) Procedimiento para la obtencion de iodacetamidas
ES535291A0 (es) Procedimiento para la obtencion de agentes termosensibilizadores
ES536491A0 (es) Procedimiento para preparar nuevos compuestos de imidazolidinon-prostaglandinas
ES552495A0 (es) Procedimiento para la obtencion de compuestos de 2-heterociclil-6-hidroxi-alquilo inferior-2-penem

Legal Events

Date Code Title Description
PC1A Transfer granted
FD1A Patent lapsed

Effective date: 20050905